A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with heterozygous familial hypercholesterolemia. The primary hypothesis is that MK-0616 is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.
Epistemonikos ID: 84517d705c628dc6bbbc6bc5b5d83be173ca1870
First added on: May 15, 2024